Literature DB >> 4943989

Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia.

J Paasikivi, F Wahlberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4943989     DOI： 10.1007/bf01219465

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  9 in total

1.  Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus.

Authors:  S S FAJANS; J W CONN
Journal:  Diabetes       Date:  1960 Mar-Apr       Impact factor: 9.461

2.  The relation between glucose tolerance and atherosclerotic vascular disease.

Authors:  K J Kingsbury
Journal:  Lancet       Date:  1966-12-24       Impact factor: 79.321

3.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

Authors:  C L Meinert; G L Knatterud; T E Prout; C R Klimt
Journal:  Diabetes       Date:  1970       Impact factor: 9.461

4.  The effect of treatment of moderate hypergly- caemia on the incidence of arterial disease.

Authors:  H Keen; R J Jarrett; C Chlouverakis; D R Boyns
Journal:  Postgrad Med J       Date:  1968-12       Impact factor: 2.401

5.  Glucose tolerance, plasma insulin and lipids in relation to adipose tissue cellularity in men after myocardial infarction.

Authors:  P Berchtold; P Björntorp; A Gustafson; B Lindholm; G Tibblin; L Wilhelmsen
Journal:  Acta Med Scand       Date:  1972 Jan-Feb

Review 6.  Coronary and precoronary care.

Authors:  B Lown; M D Klein; P I Hershberg
Journal:  Am J Med       Date:  1969-05       Impact factor: 4.965

7.  The prevalence of coronary heart disease and associated factors in an Australian rural community.

Authors:  T A Welborn; G N Cumpston; K J Cullen; D H Curnow; M G McCall; N S Stenhouse
Journal:  Am J Epidemiol       Date:  1969-05       Impact factor: 4.897

8.  Blood-sugar and arterial disease.

Authors:  H Keen; G Rose; D A Pyke; D Boyns; C Chlouverakis
Journal:  Lancet       Date:  1965-09-11       Impact factor: 79.321

9.  Long-term tolbutamide treatment after myocardial infarction. A clinical and biochemical study of 178 patients without overt diabetes.

Authors:  J Paasikivi
Journal:  Acta Med Scand Suppl       Date:  1970
  9 in total
  9 in total

1.  Oral hypoglycaemic agents.

Authors:  D R Hadden
Journal:  Ir J Med Sci       Date:  1973-05       Impact factor: 1.568

2.  Preventive effect of gliclazide on experimental atherosclerosis in rabbits.

Authors:  G Marquié
Journal:  Diabetologia       Date:  1978-04       Impact factor: 10.122

Review 3.  Misunderstanding or error? The UGDP report after four years.

Authors:  S Marigo; L Adezati; P Burnetti; G Pozza; L Robba; G Urbinati
Journal:  Acta Diabetol Lat       Date:  1974 Sep-Oct

Review 4.  Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.

Authors:  A Evans; A J Krentz
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 5.  Comparative tolerability of sulphonylureas in diabetes mellitus.

Authors:  A D Harrower
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 6.  Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

Authors:  G Leibowitz; E Cerasi
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

Review 7.  Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?

Authors:  P Smits; T Thien
Journal:  Diabetologia       Date:  1995-01       Impact factor: 10.122

Review 8.  Trade-offs in treatment alternatives for non-insulin-dependent diabetes mellitus.

Authors:  R M Kaplan; T G Ganiats
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

9.  Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbits.

Authors:  Najah R Hadi; Fadhil Al-Amran; Mohammad A A Hussein; Fadhil A Rezeg
Journal:  J Cardiovasc Dis Res       Date:  2012-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.